- Home
- GELS vs PTHS Comparison
GELS vs PTHS Comparison
Compare GELS & PTHS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GELS
- PTHS
- Stock Information
- Founded
- GELS 2018
- PTHS 2002
- Country
- GELS Australia
- PTHS United States
- Employees
- GELS N/A
- PTHS N/A
- Industry
- GELS
- PTHS
- Sector
- GELS
- PTHS
- Exchange
- GELS NYSE
- PTHS NYSE
- Market Cap
- GELS 15.9M
- PTHS 17.1M
- IPO Year
- GELS 2024
- PTHS N/A
- Fundamental
- Price
- GELS $1.62
- PTHS $20.86
- Analyst Decision
- GELS
- PTHS
- Analyst Count
- GELS 0
- PTHS 0
- Target Price
- GELS N/A
- PTHS N/A
- AVG Volume (30 Days)
- GELS 191.0K
- PTHS 164.3K
- Earning Date
- GELS 02-15-2025
- PTHS 08-12-2025
- Dividend Yield
- GELS N/A
- PTHS N/A
- EPS Growth
- GELS N/A
- PTHS N/A
- EPS
- GELS N/A
- PTHS N/A
- Revenue
- GELS $233,830.00
- PTHS N/A
- Revenue This Year
- GELS N/A
- PTHS N/A
- Revenue Next Year
- GELS N/A
- PTHS $371.28
- P/E Ratio
- GELS N/A
- PTHS N/A
- Revenue Growth
- GELS 10.19
- PTHS N/A
- 52 Week Low
- GELS $0.77
- PTHS $4.50
- 52 Week High
- GELS $5.50
- PTHS $54.29
- Technical
- Relative Strength Index (RSI)
- GELS N/A
- PTHS N/A
- Support Level
- GELS N/A
- PTHS N/A
- Resistance Level
- GELS N/A
- PTHS N/A
- Average True Range (ATR)
- GELS 0.00
- PTHS 0.00
- MACD
- GELS 0.00
- PTHS 0.00
- Stochastic Oscillator
- GELS 0.00
- PTHS 0.00
About GELS GELTEQ LIMITED
Gelteq Ltd is a clinical and science-based company that is focused on developing and commercializing white-label gel-based delivery solutions to preserve the simplicity, accessibility and efficacy of oral delivery without the impediments traditionally associated with other oral delivery methods, with prescription drugs, nutraceuticals, pet care, and other products. It is engaged in the development and testing of a gel-based delivery system for humans and pets. Its principal products are edible gels.
About PTHS PELTHOS THERAPEUTICS INC
Pelthos Therapeutics Inc is a clinical-stage biotechnology company developing and commercializing novel, non-opioid, non-addictive therapeutics to alleviate pain. The initial clinical focus is to selectively target the sodium ion channel known as NaV1.7 for the treatment of various types of chronic, visceral pain, acute and chronic eye pain, and post-surgical nerve blocks. Its pipeline includes CC8464 for ISFN and EM and CT2000 for Acute and CHronic Eye Pain-Dry Eye Disease.